New research suggests that nintedanib, combined with standard chemotherapy, causes a total remission of tumors in 50% of patients suffering from early HER-2- negative breast cancer. These are the conclusions of the Phase I Clinical Trial, sponsored by the Spanish National Cancer Research Centre (CNIO) and carried out by CNIO (and) #769;s Breast Cancer Clinical Research Unit. The study has been published today in iBritish Journal of Cancer/i, which belongs to Nature ...Sunday 14 September 2014
First Clinical Trial on HER-2-Negative Breast Cancer With Nintedanib Completed by CNIO
New research suggests that nintedanib, combined with standard chemotherapy, causes a total remission of tumors in 50% of patients suffering from early HER-2- negative breast cancer. These are the conclusions of the Phase I Clinical Trial, sponsored by the Spanish National Cancer Research Centre (CNIO) and carried out by CNIO (and) #769;s Breast Cancer Clinical Research Unit. The study has been published today in iBritish Journal of Cancer/i, which belongs to Nature ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment